At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 6 enrolled
Drug / intervention
Interleukin-2biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy of Low Dose, Subcutaneous Interleukin-2 (IL-2) to Expand Endogenous Regulatory T-Cells in Liver Transplant Recipients
In Brief
A Phase 2 clinical trial evaluating Interleukin-2 for Liver Transplantation. Completed, enrolled 6 participants across 1 site.
Detailed Summary
The purpose of this investigation is to study if very low dose IL-2, given to liver transplant patients by subcutaneous (under the skin) injections, over a 4 week period of time, will cause an increase in the number of Treg cells in the blood.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLiver Transplantation
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedApr 2016
Enrollment StartNov 2016
Primary CompletionJul 2022
TodayJul 2026
First PostedApr 15, 2016
Enrollment StartNov 1, 2016
Primary CompletionJul 1, 2022
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 10.2 years ago
Interventions
Interleukin-2biological
Subjects will self-administer low dose IL-2 as subQ injection (0.30 MIU per meter squared body surface area) for 4 weeks.